[
  {
    "nct_id": "NCT_MOCK_99000001",
    "source": "ctg",
    "title": "Phase 3 Empagliflozin in Type 1 Diabetes with Diabetic Kidney Disease (EMPA-T1-KID)",
    "abstract": "Status changed: Recruiting -> Active, not recruiting. Primary outcome: eGFR slope at 156 weeks. Secondary: UACR, severe hypoglycemia, all-cause mortality. Population: T1DM with eGFR 30-90.",
    "phase": "Phase 3",
    "jif": 0.0,
    "days_since_pub": 1
  },
  {
    "nct_id": "NCT_MOCK_99000002",
    "source": "ctg",
    "title": "Mazdutide vs Semaglutide in T2DM-DKD with eGFR <30 (DUAL-RENAL)",
    "abstract": "Status changed: Not yet recruiting -> Recruiting. Primary: composite MAKE (kidney failure, sustained eGFR decline >=40%, kidney death). Secondary: UACR, hyperkalemia, all-cause death.",
    "phase": "Phase 3",
    "jif": 0.0,
    "days_since_pub": 2
  },
  {
    "nct_id": "NCT_MOCK_99000003",
    "source": "ctg",
    "title": "Apararenone Add-on to Dapagliflozin in Macroalbuminuric DKD",
    "abstract": "Status changed: Active, not recruiting -> Completed. Primary: change in UACR. Secondary: eGFR slope, hyperkalemia incidence.",
    "phase": "Phase 2",
    "jif": 0.0,
    "days_since_pub": 1
  },
  {
    "nct_id": "NCT_MOCK_99000004",
    "source": "ctg",
    "title": "Cagrisema in Normoalbuminuric Type 2 Diabetic Kidney Disease",
    "abstract": "Status: Recruiting. Primary: eGFR slope at 104 weeks. Secondary: UACR, severe hypoglycemia. Population: T2DM with normoalbuminuria and eGFR 45-89.",
    "phase": "Phase 2",
    "jif": 0.0,
    "days_since_pub": 3
  },
  {
    "nct_id": "NCT_MOCK_99000005",
    "source": "ctg",
    "title": "KBP-5074 (Ocedurenone) in Advanced CKD with Type 2 Diabetes",
    "abstract": "Status changed: Recruiting -> Suspended (administrative). Primary: change in UACR at week 12. Secondary: hyperkalemia, eGFR slope.",
    "phase": "Phase 2b",
    "jif": 0.0,
    "days_since_pub": 5
  }
]